A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.
Sebastian Bauer,Robin L. Jones,Suzanne George,Hans Gelderblom,Patrick Schöffski,Margaret von Mehren,John Zalcberg,Yoon-Koo Kang,Albiruni Ryan Abdul Razak,Jonathan C. Trent,Steven Attia,Axel Le Cesne,William M. Reichmann,Kam Sprott,Haroun Achour,Matthew L. Sherman,Rodrigo Ruiz-Soto,Jean-Yves Blay,Michael Heinrich +18 more
TL;DR: In this article , the authors presented exploratory baseline ctDNA results from INTRIGUE, an open-label, phase 3 study that enrolled adult patients with advanced GIST who progressed on or had intolerance to imatinib (NCT03673501).
Journal ArticleDOI
Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
John A. Martignetti,Albiruni Ryan Abdul Razak,Ying Chen,Nashat Y. Gabrail,John F. Gerecitano,Catalina Camacho,Elena Pereira,Peter Dottino,Sharon Shacham,Dilara McCauley,Tami Rashal,Jean-Richard Saint-Martin,Eran Shacham,Darcy Vincett,Michael Kauffman,Mansoor Raza Mirza,Morten Dræby Sørensen +16 more
TL;DR: A large number of tumor suppressor proteins are transported out of the body through the TSP pathway, and increased XPO1 expression has been linked to progression of OvCa and is an independent poor prognostic for survival.
Journal ArticleDOI
1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Filip Janku,Ping Chi,Michael Heinrich,M. von Mehren,R.L. Jones,Kristen N. Ganjoo,Jonathan C. Trent,Hans Gelderblom,Albiruni Ryan Abdul Razak,Michael S. Gordon,Neeta Somaiah,Julia Jennings,K. Shi,Rodrigo Ruiz-Soto,Suzanne George +14 more
Journal ArticleDOI
Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.
Robin Kate Kelley,Lillian L. Siu,Katherine Van Loon,Anthony W. Tolcher,Albiruni Ryan Abdul Razak,Sharvina Ziyeh,Muralidhar Beeram,Philippe L. Bedard,Rebecca Arcos,Bo Gao,Pamela Trail,Lieve Adriaens,Carrie Brownstein,Israel Lowy,Kyriakos P. Papadopoulos +14 more
TL;DR: Nesvacumab is an Ang2 selective, human MAb that potently blocks signaling through the Tie2 receptor, inhibiting tumor angiogenesis and growth in mouse xenograft models of human solid tumors.
Journal ArticleDOI
Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.
Suzanne George,Michael Heinrich,Albiruni Ryan Abdul Razak,Ping Chi,Michael S. Gordon,Kristen N. Ganjoo,Margaret von Mehren,Neeta Somaiah,Jonathan C. Trent,Ying Su,Rodrigo Ruiz-Soto,Oliver Rosen,Filip Janku +12 more
TL;DR: GIST is driven by primary and secondary driver mutations in KIT/PDGFRα and cell-free tumor (ct) DNA and may provide the opportunity to assess disease status and response to therapy.